PMID- 30888515
OWN - NLM
STAT- MEDLINE
DCOM- 20190506
LR  - 20200225
IS  - 1432-1335 (Electronic)
IS  - 0171-5216 (Linking)
VI  - 145
IP  - 5
DP  - 2019 May
TI  - TRPM2 mediates distruption of autophagy machinery and correlates with the grade 
      level in prostate cancer.
PG  - 1297-1311
LID - 10.1007/s00432-019-02898-z [doi]
AB  - PURPOSE: Transient receptor potential melastatin 2 (TRPM2), a calcium-permeable 
      ion channel, is shown as a prognostic marker candidate in prostate cancer (PCa) 
      and an important regulator of autophagy. We aimed to determine the changes in 
      TRPM2 and autophagic-apoptotic gene expression levels in human prostate 
      adenocarcinomas, and to investigate the affect of TRPM2 on autophagic pathways in 
      PC-3 cell line. METHODS: Human prostate tissues were classified considering the 
      grade levels and were divided into the control, BPH, and grade 1-5 groups. mRNA 
      expression levels of genes were determined by qPCR. In addition, TRPM2 was 
      evaluated immunohistochemically for each group. In PC-3 cell line, TRPM2 was 
      silenced through siRNA transfection, and autophagy induction was analyzed by 
      acridine orange (AO) staining. RESULTS: The qPCR and immunoreactivity results 
      showed that the increased TRPM2 expression levels in human PCa samples were 
      paralleled with higher grade levels. The autophagic-apoptotic gene expressions 
      showed high variability in different grade levels. Also, silencing TRPM2 in PC-3 
      cells altered autophagic gene expressions and caused autophagy induction 
      according to the AO staining results. CONCLUSION: We showed that the 
      autophagy-TRPM2 association may take place in the molecular basis of PCa and 
      accordingly this connection may be targeted as a new therapeutic approach in PCa.
FAU - Tektemur, Ahmet
AU  - Tektemur A
AUID- ORCID: 0000-0002-2476-0413
AD  - Department of Medical Biology, Faculty of Medicine, Firat University, Elazig, 
      Turkey. atektemur@firat.edu.tr.
FAU - Ozaydin, Seda
AU  - Ozaydin S
AD  - Department of Medical Biology, Faculty of Medicine, Firat University, Elazig, 
      Turkey.
FAU - Etem Onalan, Ebru
AU  - Etem Onalan E
AD  - Department of Medical Biology, Faculty of Medicine, Firat University, Elazig, 
      Turkey.
FAU - Kaya, Nalan
AU  - Kaya N
AD  - Department of Histology, Faculty of Medicine, Firat University, Elazig, Turkey.
FAU - Kuloglu, Tuncay
AU  - Kuloglu T
AD  - Department of Histology, Faculty of Medicine, Firat University, Elazig, Turkey.
FAU - Ozercan, Ibrahim Hanifi
AU  - Ozercan IH
AD  - Department of Medical Pathology, Faculty of Medicine, Firat University, Elazig, 
      Turkey.
FAU - Tekin, Suat
AU  - Tekin S
AD  - Department of Physiology, Faculty of Medicine, Inonu University, Malatya, Turkey.
FAU - Elyas, Halit Mohammed
AU  - Elyas HM
AD  - Department of Medical Biology, Faculty of Medicine, Firat University, Elazig, 
      Turkey.
LA  - eng
GR  - TF.14.37/Firat University Scientific Research Projects Management Unit/
PT  - Journal Article
DEP - 20190319
PL  - Germany
TA  - J Cancer Res Clin Oncol
JT  - Journal of cancer research and clinical oncology
JID - 7902060
RN  - 0 (RNA, Messenger)
RN  - 0 (RNA, Small Interfering)
RN  - 0 (TRPM Cation Channels)
RN  - 0 (TRPM2 protein, human)
SB  - IM
MH  - Apoptosis/genetics
MH  - Autophagy/*genetics
MH  - Cell Line, Tumor
MH  - Cell Survival/genetics
MH  - Gene Expression
MH  - Humans
MH  - Immunohistochemistry
MH  - Male
MH  - Neoplasm Grading
MH  - Prostatic Neoplasms/*etiology/*metabolism/pathology
MH  - RNA Interference
MH  - RNA, Messenger/genetics
MH  - RNA, Small Interfering/genetics
MH  - TRPM Cation Channels/*genetics/*metabolism
OTO - NOTNLM
OT  - Autophagy
OT  - Gene expression
OT  - Ion channels
OT  - Prostate cancer
OT  - Transient receptor potential melastatin 2 (TRPM2)
EDAT- 2019/03/20 06:00
MHDA- 2019/05/07 06:00
CRDT- 2019/03/20 06:00
PHST- 2019/01/02 00:00 [received]
PHST- 2019/03/13 00:00 [accepted]
PHST- 2019/03/20 06:00 [pubmed]
PHST- 2019/05/07 06:00 [medline]
PHST- 2019/03/20 06:00 [entrez]
AID - 10.1007/s00432-019-02898-z [pii]
AID - 10.1007/s00432-019-02898-z [doi]
PST - ppublish
SO  - J Cancer Res Clin Oncol. 2019 May;145(5):1297-1311. doi: 
      10.1007/s00432-019-02898-z. Epub 2019 Mar 19.